When to go up to 5mg Mounjaro: what the evidence says

What the SURMOUNT trials tell us about the 2.5mg-to-5mg transition

The SURMOUNT-1 trial, published in the New England Journal of Medicine, tested tirzepatide at 5mg, 10mg and 15mg against placebo over 72 weeks in adults with obesity. The 5mg dose produced average body-weight reductions that were meaningfully greater than placebo, establishing it as an active therapeutic dose rather than a stepping-stone with no effect of its own. The 2.5mg starting dose was included in the trial design precisely as an induction period — participants moved up after four weeks as a matter of protocol, not because anyone decided they were ready in a subjective sense.

That protocol reflects a well-understood principle in the trial data: gastro-intestinal side effects are most pronounced when the dose first rises, so a gradual ascent reduces nausea, vomiting and other GI disturbance. Starting at 2.5mg and spending a full four weeks there means the 5mg increase tends to land on a system that has already adapted to the mechanism of the medicine. The NHS tirzepatide information page reflects this same schedule.

One thing the evidence is clear about: there is no shortcut. Going up before four weeks have elapsed does not improve outcomes and meaningfully increases the chance of side effects that make continuing difficult.

How the 5mg step-up is assessed in practice

At four weeks on 2.5mg, the question your prescriber asks is straightforward: did you tolerate the first pen well enough to move up? That means reviewing whether side effects were manageable rather than severe, whether you injected consistently, and whether any new health information has emerged since your initial consultation.

If nausea or other GI symptoms were significant throughout week three and week four, a prescriber may recommend staying at 2.5mg for a second four-week pen rather than stepping up immediately. This is not a failure; it is the licensed schedule working as intended. What makes the 5mg move the right one depends on your individual tolerance profile, not on a fixed calendar date.

Timing also matters in a practical sense. If your four-week pen runs out mid-week or just before a bank holiday, it is worth ordering your next pen before that point, a straightforward question about cost and ordering that our team fields regularly. A gap of more than a couple of days between pens is worth flagging to your prescriber.

At nume, repeat orders are not processed automatically. A prescriber looks at your update before your next pen is dispensed. That applies at every step, including the 2.5mg-to-5mg move. It takes a few minutes on your part and keeps the clinical picture current.

Side effects to be aware of as the dose rises

The GI profile of tirzepatide tends to peak around dose increases. When you move to 5mg, some people notice a return of nausea or loose stools that had settled during the starter pen. This is common and usually short-lived, often resolving within a week or two as the body adjusts to the higher dose.

Symptoms worth reporting promptly include severe stomach pain that radiates toward the back (a sign that requires urgent medical attention given the known, if infrequent, association between GLP-1 medicines and acute pancreatitis, highlighted in a January 2026 MHRA Drug Safety Update), significant dehydration from persistent vomiting or diarrhoea, and any allergic reaction. None of these should be waited out at home.

Side effects that are mild and settling do not usually mean the 5mg step was wrong. Contacting our aftercare team if you are unsure is always the right call, our prescribers are available seven days a week. You can also read about dose increases across the full tirzepatide schedule for a broader picture of what each step involves.

What happens after 5mg, and how far the ladder goes

Five milligrams is the first of five active therapeutic doses, the full licensed range in the UK is 2.5, 5, 7.5, 10, 12.5 and 15mg. Each step follows the same four-week minimum rule, and if you want to understand when the right moment to increase your Mounjaro dose arrives, the same principles of tolerance and prescriber sign-off apply throughout. Most people reach their maintenance dose somewhere between 5mg and 15mg; that ceiling is determined by tolerance and clinical response rather than a fixed destination everyone reaches.

NICE's appraisal of tirzepatide, TA1026, notes that if less than 5% body weight has been lost after six months at the highest tolerated dose, continuing should be reviewed. That clause is about long-term maintenance, not about the early titration phase. At 5mg, the expectation is that weight loss will begin to become noticeable, though the rate varies between individuals.

For a fuller sense of how Mounjaro works as a treatment, including what to expect across the programme, our treatment overview covers the picture from first injection to maintenance. And if you are weighing up when to move up beyond 5mg down the line, the same principles apply: tolerance, timing and a prescriber's sign-off at every step.

If you have not yet started and want to understand whether Mounjaro is clinically appropriate for you, the right place to begin is a free consultation with our prescribers.

Start your free consultation and a GPhC-registered prescriber will review your case the same day.